Carlos Becerra
Hoag Memorial Hospital Presbyterian · Baylor University Medical Cancer Hospital · Baylor Research Institute/Texas Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Carlos Becerra as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:16 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07344220 · Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye ConjugateHoag Memorial Hospital Presbyterian · enrolling by invitation · Metastatic Pancreatic Adenocarcinoma, Pancreatic Cancer · principal investigator
- Ph1NCT04878484 · Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid TumorsAthenex, Inc. · withdrawn · Advanced Solid Tumor · principal investigator
- Early Ph1NCT02550327 · Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic CancerBaylor Research Institute · completed · Pancreatic Adenocarcinoma · principal investigator
- Ph1NCT02548169 · Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic CancerBaylor Research Institute · terminated · Pancreatic Cancer · principal investigator
- Ph1NCT02021422 · A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard ChemotherapyBaylor Research Institute · completed · Pancreas Cancer · principal investigator
- Ph1NCT01837667 · Phase I Study of LB-100 With Docetaxel in Solid TumorsLixte Biotechnology Holdings, Inc. · completed · Tumors, Neoplasms, Cancer · principal investigator
- Ph2NCT00319735 · Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction CarcinomasNasser Hanna, M.D. · completed · Esophageal Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:16 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- 51 citationsRCR 4.9
- Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.Invest New Drugs · 201140 citationsRCR 1.0
- A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers.Invest New Drugs · 201621 citationsRCR 0.7
- Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction.Oncologist · 202512 citationsRCR 2.4